This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
In July 2014, a panel of three strains of Streptococcus pneumoniae and two simulated samples of cerebrospinal fluid was sent to 30 reference laboratories in the IBD-labnet surveillance network for quality assessment testing. This report summarises the diagnostic results submitted by the participating laboratories.